Global Blood Therapeutics (NASDAQ: GBT) and CytRx (NASDAQ:CYTR) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, dividends, earnings and profitability.

Valuation and Earnings

This table compares Global Blood Therapeutics and CytRx’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Global Blood Therapeutics N/A N/A -$82.46 million ($2.55) -22.20
CytRx $200,000.00 261.20 -$50.76 million ($2.84) -0.67

CytRx has higher revenue and earnings than Global Blood Therapeutics. Global Blood Therapeutics is trading at a lower price-to-earnings ratio than CytRx, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Global Blood Therapeutics and CytRx’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Global Blood Therapeutics N/A -40.04% -37.24%
CytRx N/A -210.45% -72.41%

Analyst Ratings

This is a breakdown of recent ratings for Global Blood Therapeutics and CytRx, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Global Blood Therapeutics 0 0 13 0 3.00
CytRx 0 0 2 0 3.00

Global Blood Therapeutics currently has a consensus price target of $64.08, suggesting a potential upside of 13.21%. CytRx has a consensus price target of $24.00, suggesting a potential upside of 1,169.84%. Given CytRx’s higher possible upside, analysts plainly believe CytRx is more favorable than Global Blood Therapeutics.

Institutional and Insider Ownership

85.7% of Global Blood Therapeutics shares are held by institutional investors. Comparatively, 44.8% of CytRx shares are held by institutional investors. 5.3% of Global Blood Therapeutics shares are held by insiders. Comparatively, 5.3% of CytRx shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Global Blood Therapeutics beats CytRx on 5 of the 9 factors compared between the two stocks.

Global Blood Therapeutics Company Profile

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD). The Company is evaluating GBT440 in SCD in a Phase III clinical trial of GBT440 in adult and adolescent patients with SCD. GBT440 inhibits abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. The Company is also engaged in other research and development activities targeted towards hereditary angioedema (HAE). The Company’s GBT440 is an investigational drug that increases hemoglobin’s affinity for oxygen by binding to the alpha-chain of hemoglobin. GBT440 has been observed to keep a proportion of sickle hemoglobin (HbS), in its oxygenated state, where it cannot participate in polymerization.

CytRx Company Profile

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy. It is also involved in evaluating aldoxorubicin in a Phase IIb clinical trial in small cell lung cancer; a Phase II clinical trial in human immunodeficiency virus-related Kaposi’s sarcoma; a Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); a Phase Ib trial in combination with ifosfamide in patients with STS, and a Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It is engaged in the pre-clinical development for DK049, an anti-cancer drug conjugate that utilizes its Linker Activated Drug Release (LADR) technology.

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.